SMLR · As filed with the SEC
Semler Scientific cash flow statement, by fiscal year
The statement as Semler Scientific presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Statements of Cash Flows · USD
| USD | FY2024 Year ended Dec 31, 2024 | FY2023 Year ended Dec 31, 2023 | FY2022 Year ended Dec 31, 2022 | FY2021 Year ended Dec 31, 2021 | FY2020 Year ended Dec 31, 2020 | FY2019 Year ended Dec 31, 2019 | Year ended Dec 31, 2018 Year ended Dec 31, 2018 | Year ended Dec 31, 2017 Year ended Dec 31, 2017 |
|---|---|---|---|---|---|---|---|---|
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||||
| Net income | — | — | — | 17,222,000 | 14,007,000 | 15,084,000 | 5,014,000 | — |
| Net income | 40,899,000 | 20,583,000 | 14,325,000 | — | — | — | — | — |
| Reconciliation of Net Income to Net Cash Provided by Operating Activities: | ||||||||
| Amortization of debt discount | — | — | — | — | — | — | 22,000 | — |
| Accretion of non-cash interest | — | — | — | — | — | — | 231,000 | — |
| Depreciation | 579,000 | 599,000 | 589,000 | 628,000 | 576,000 | 632,000 | 503,000 | — |
| Deferred tax expense (income) | 5,727,000 | (664,000) | (351,000) | 408,000 | 2,136,000 | (4,501,000) | 0 | — |
| Loss on disposal of assets for lease | 298,000 | 369,000 | 463,000 | 362,000 | 271,000 | 206,000 | 200,000 | — |
| Write off of prepaid software licenses | — | 2,476,000 | — | — | — | — | — | — |
| Gain on short-term investments | — | (151,000) | (77,000) | — | — | — | — | — |
| Loss on disposal of inventory | — | — | — | 1,202,000 | — | — | — | — |
| Allowance for credit losses | (88,000) | 268,000 | 103,000 | 63,000 | 55,000 | 48,000 | 46,000 | — |
| Non-cash interest income | — | — | — | — | (12,000) | — | — | — |
| Gain on sale of Mellitus Health Inc. securities | — | — | — | — | (442,000) | — | — | — |
| Change in fair value of notes held for investment | (128,000) | 307,000 | — | — | — | — | — | — |
| Change in fair value of digital assets | (24,933,000) | — | — | — | — | — | — | — |
| Stock-based compensation | 862,000 | 944,000 | 741,000 | 749,000 | 253,000 | 365,000 | 601,000 | — |
| Impairment of long-term investments | — | 337,000 | — | — | — | — | — | — |
| Changes in Operating Assets and Liabilities: | ||||||||
| Trade accounts receivable | 1,844,000 | (2,508,000) | (367,000) | (874,000) | 623,000 | (734,000) | (1,503,000) | — |
| Inventory | 88,000 | 24,000 | 81,000 | (1,412,000) | — | — | — | — |
| Prepaid expenses and other current assets | (865,000) | (603,000) | 2,576,000 | (2,657,000) | (1,160,000) | (63,000) | (42,000) | — |
| Other non-current assets | 85,000 | 96,000 | (2,510,000) | 86,000 | (403,000) | — | — | — |
| Accounts payable | (262,000) | (433,000) | 392,000 | (234,000) | 339,000 | 58,000 | (208,000) | — |
| Accrued expenses | 671,000 | (246,000) | 1,310,000 | 638,000 | (1,235,000) | 1,113,000 | (71,000) | — |
| Deferred revenue | — | — | — | — | 8,000 | 520,000 | (96,000) | — |
| Other current and non-current liabilities | (367,000) | (68,000) | 188,000 | (125,000) | 401,000 | — | — | — |
| Net Cash Provided by Operating Activities | 24,410,000 | 21,330,000 | 17,463,000 | 16,056,000 | 15,417,000 | 12,728,000 | 4,697,000 | — |
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||||||||
| Additions to property and equipment | (51,000) | (345,000) | (476,000) | (318,000) | (149,000) | (174,000) | (138,000) | — |
| Proceeds from sale of property and equipment | — | — | — | — | — | — | 1,000 | — |
| Payment for long-term note receivable from SYNAPS Dx | — | — | — | — | (457,000) | — | — | — |
| Payment for long-term note receivable from Mellitus Health Inc. | — | — | — | — | (59,000) | — | — | — |
| Purchase of shares of preferred stock from Mellitus Health Inc. | — | — | — | — | (250,000) | — | — | — |
| Payment for long-term note receivable from Mellitus Health Inc. | — | — | — | — | (1,424,000) | — | — | — |
| Proceeds from sale of Mellitus Health Inc. | — | — | — | — | 1,942,000 | — | — | — |
| Notes receivable | — | (1,000,000) | — | — | — | — | — | — |
| Proceeds from maturities of short-term investments | — | 78,093,000 | — | — | — | — | — | — |
| Purchase of notes held for investment | (500,000) | — | (4,679,000) | — | — | — | — | — |
| Purchase of digital assets | (189,700,000) | — | — | — | — | — | — | — |
| Purchase of short-term investments | — | (57,869,000) | (19,996,000) | — | — | — | — | — |
| Purchase of assets for lease | — | (483,000) | (1,684,000) | (507,000) | (912,000) | (1,524,000) | (706,000) | — |
| Proceeds from sale (purchase) of assets for lease | 269,000 | — | — | — | — | — | — | — |
| Net Cash (Used in) Provided by Investing Activities | (189,982,000) | 18,396,000 | (26,835,000) | (825,000) | (1,309,000) | (1,698,000) | (843,000) | — |
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||||
| Proceeds from issuance of common stock | 119,602,000 | — | — | — | — | — | — | — |
| Taxes paid related to net settlement of equity awards | (874,000) | (3,510,000) | (114,000) | (45,000) | — | — | — | — |
| Common stock warrants acquired | — | (1,949,000) | — | — | — | (6,633,000) | — | — |
| Proceeds from exercise of warrants | — | — | — | — | — | — | 414,000 | — |
| Treasury stock acquired | — | — | (4,991,000) | — | — | — | — | — |
| Stock issuance expenses | (3,000,000) | — | — | — | — | — | — | — |
| Proceeds from exercise of stock options | 1,464,000 | 51,000 | 168,000 | 58,000 | 230,000 | 60,000 | 456,000 | — |
| Payments of loans payable | — | — | — | — | — | — | (2,897,000) | — |
| Net Cash Provided by (Used in) Financing Activities | 117,192,000 | (5,408,000) | (4,937,000) | 13,000 | 230,000 | (6,573,000) | (2,027,000) | — |
| NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS | (48,380,000) | 34,318,000 | (14,309,000) | 15,244,000 | 14,338,000 | 4,457,000 | 1,827,000 | — |
| CASH, BEGINNING OF PERIOD | — | — | — | 22,079,000 | 7,741,000 | 3,284,000 | 1,457,000 | — |
| CASH, END OF PERIOD | — | — | — | — | 22,079,000 | 7,741,000 | 3,284,000 | — |
| Cash paid for interest | — | — | — | — | — | — | 575,000 | — |
| CASH, CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING OF PERIOD | 57,332,000 | 23,014,000 | 37,323,000 | 22,079,000 | — | — | — | — |
| CASH, CASH EQUIVALENTS AND RESTRICTED CASH, END OF PERIOD | 8,952,000 | 57,332,000 | 23,014,000 | 37,323,000 | — | — | — | — |
| Supplemental Disclosure of Cash Flow Information: | ||||||||
| Issuance of shares to settle related party loan | — | — | — | — | — | — | 294,000 | — |
| Cash paid for taxes | 2,260,000 | 4,060,000 | 2,400,000 | 2,647,000 | 285,000 | 123,000 | 18,000 | — |
| Long-term note receivable from SYNAPS Dx settled by stock issuance | — | — | — | — | 512,000 | — | — | — |
| Exchange of SMLR common stock for preferred stock of Private company #2 | — | — | — | — | 2,230,000 | — | — | — |
| Exercised put option of 211,928 common stock in SYNAPS Dx for 40,922 common stock of the company | — | — | — | (2,230,000) | — | — | — | — |
| Long-term note receivable from Mellitus Health Inc. settled by stock issuance | — | — | — | — | 59,000 | — | — | — |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.